HAVN Life Sciences's receivables is $290K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (January 2023), HAVLF shows a receivables of $290K. That compares with $870K in the prior-year period — down 66.2% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, HAVLF's receivables is now $290K (was $870K) — a 66.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether HAVN Life Sciences is outperforming or lagging.
Tracking HAVLF's receivables over time shows whether HAVN Life Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $290K That compares with $870K in the prior-year period — down 66.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has HAVN Life Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $290K) with ownership activity and broader fundamentals.
HAVN Life Sciences's receivables is $290K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.